It is the procedure in which pathological tissue is taken to detect the presence or absence of prostate cancer in patients who are found to be elevated in prostate biopsy blood tests (PSA) or abnormality with digital rectal examination.
In traditional systematic prostate biopsy, tissue pieces are taken from 12 quadrants of the prostate and examined under ultrasound guidance. Since the sensitivity of ultrasonography (USG) is low, the diagnosis may not be accurate, especially in low-stage prostate cancers.
With the help of technological developments in recent years, multiparametric MR has begun to detect the cancer focus in the prostate much better. Owing to MRI applied to the patient before prostate biopsy, the rate of detection for prostate cancer increases.
The procedure is completed by going to the focus or prostate area seen in MRI with the ultrasonography used during the procedure and removing the tissue pieces. MR fusion biopsy can be considered as a kind of navigation system by developing this method and is the highest point of this subject. It is a system that minimizes the person-dependent estimated tissue removal.
Before MR fusion prostate biopsy, multiparametric MR is applied to the patient to detect a lesion with suspected cancer located in the prostate. During the procedure, the ultrasonography device, which displays the prostatic tissues, is guided by the fusion device of the lesion, which is suspected of cancer, seen in MRI.
Thus, because of this perfect system, the probability of diagnosis of cancerous tissues rises to a very high level. Considering the anxiety of patients during prostate biopsy and possibility of infection after biopsy, it also saves them from repetitive unnecessary biopsies.
Note: Page contents are for informational purposes only and a doctor's application is required for your diagnosis and treatment.